Learn from renowned clinical expert, George J. Alangaden, M.D., as he discusses how Henry Ford Health System (HFHS) implemented T2MR and the T2Candida Panel as part of their sepsis protocol for the ...

During the webinar, Dr. Snežana Jovanović will share her experience with T2 Biosystems sepsis diagnostics. Through case studies, participants will examine the role of early diagnosis of bloodstream ...

LEXINGTON, Mass.--(BUSINESS WIRE)--T2 Biosystems today announced the completion of a $40 million financing to support the clinical programs and commercialization of T2Candida™, the Company’s flagship ...

LEXINGTON, Mass., April 27, 2021 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced that Expert Review of Medical ...

Please provide your email address to receive an email when new articles are posted on . T2 Biosystems is the first company to receive FDA-clearance for their T2Candida Panel and, more recently, their ...

Bayer will use T2 Biosystems’ T2 Magnetic Resonance technology platform (T2MR ®) under a multiyear hemostasis research collaboration whose value was not disclosed. The collaboration, disclosed today ...

T2 Biosystems, Inc. has signed a multi-year agreement to provide T2 Biosystems’ T2 Magnetic Resonance technology platform, or T2MR®, for Bayer’s research and development efforts in blood coagulation ...

T2 Biosystems, a company developing direct detection products enabling superior diagnostics, today announced the publication of research supporting the Company's flagship diagnostic test, T2Candida, ...

LEXINGTON, Mass.--(BUSINESS WIRE)--T2 Biosystems, a company developing direct detection products designed to enable superior diagnostics, today announced the presentation of data highlighting the role ...

Study concludes the utilization of T2 Magnetic Resonance (T2MR®) provides faster time to detection, faster time to targeted therapy, and shortened ICU and hospital length-of-stay LEXINGTON, Mass., ...